Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma [Phase 2]

View source ↗

Summary

A Phase 2 trial of antineoplaston therapy for recurrent or refractory oligodendroglioma was terminated, and the study results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligodendroglioma

Drugs mentioned

• Antineoplaston therapy

Snippet

Sponsor: Burzynski Research Institute | Conditions: Oligodendroglioma, Adult | Phase 2 | Status: TERMINATED | Results posted: 2017-12-13